

FEB 18 2000

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

The Hedrocel Posterior Stabilized (PS) Tibial Component, Cemented

Submitter Name: Implex Corp.

Submitter Address: 80 Commerce Drive
Allendale, New Jersey 07401-1600

Contact Person(s): John Schalago or Robert Poggie

Phone Number: (201) 818-1800

Fax Number: (201) 995-9722

Date Prepared: November 29, 1999

Device Trade Name: The Implex Hedrocel PS Tibial Component, Cemented

Device Common Name: Tibial Component

Classification Name: Prosthesis, Knee, Tibial Component, Cemented

Substantial Equivalence: The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence found in the Federal Food, Drug and Cosmetic Act, as amended and as applied under 21 CFR 807, Subpart E under which a device can be marketed without premarket approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matters. No statements related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent Laws or their application by the courts.

Predicate Devices: The CKS Posterior Stabilized Knee System (the tibial component), Cemented, and the Hedrocel Unity Tibial Component, Cemented.

510(K) Summary of Safety and Effectiveness - Continued...

- Device Description:** The Implex Hedrocel PS Tibial Component, Cemented, is available in 8 thickness sizes from 10 mm to 22 mm, in 2 mm increments, and a 26 mm option; and A-P dimensions from 41 mm to 57 mm, and M-L dimensions from 62 mm to 89 mm. The Hedrocel PS Tibial Component is comprised of Hedrocel porous tantalum and UHMWPE and is intended to be implanted using the Implex Continuum Knee System Instrumentation and Surgical Protocol. In addition, the Hedrocel PS Tibial component is offered in two fixation post options; option A with hexagonal Hedrocel® posts, and option B with polyethylene fixation pegs.
- Intended Use:** The Implex Hedrocel Posterior Stabilized (PS) Tibial Component is intended for use where severe degeneration, trauma, or other pathology of the knee joint indicates cemented total knee arthroplasty. In addition, the Hedrocel PS Tibial Component is indicated for use in the presence of knee instability caused by a compromised or non-functional posterior cruciate ligament.
- Performance Data:** Previous testing of the predicate devices and associated materials support a determination of substantial equivalence.



FEB 18 2000

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. John A. Schalago, RAC
Manager, Regulatory Affairs
Implex Corporation
80 Commerce Drive
Allendale, New Jersey 07401

Re: K994076
Implex Hedrocel PS Tibial Component, Cemented
Regulatory Class: II
Product Code: JWH
Dated: November 29, 1999
Received: December 2, 1999

Dear Mr. Schalago:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 - Mr. John A. Schalago, RAC

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



James E. Dillard III
for

Acting Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

